Blockage of autonomous growth of ACHN cells by anti-renal cell carcinoma monoclonal antibody 5F4.
نویسنده
چکیده
A cultured renal carcinoma cell line, ACHN, continued to proliferate in the absence of exogenous growth factors supplied by fetal calf serum. ACHN cells had been previously used as the immunogen for the production of monoclonal antibody 5F4. Subsequent immunohistochemical studies showed that 5F4 strongly and selectively reacted with renal carcinoma cells compared with normal renal epithelium, suggesting that expression of the substance to which it was bound was amplified as a result of malignant transformation. Because renal carcinoma cells are relatively differentiated with regard to function except for elements to ensure sustained growth, the immunoreactivity patterns led to the hypothesis that 5F4 reacted with some component of a growth-stimulating pathway. The hypothesis was supported in the present work by showing that 5F4 specifically inhibited the growth of ACHN cells; ACHN cells prominently secreted a protein with a molecular mass of 178 kilodaltons that was immunoreactive with 5F4; the protein was partially purified by simple lyophilization of serum-free conditioned medium; both ACHN conditioned medium and the lyophilizate stimulated the growth of quiescent human fibroblasts and BALB/3T3 cells as well as serum-deprived human renal carcinoma cell lines ACHN, A498, Caki-1, and Caki-2. Specific immunoadsorption of the protein by affinity chromatography with 5F4 removed the growth-stimulating activity. The results demonstrated a novel growth-promoting substance secreted by ACHN cells with autologous activity as well as activity for human and murine fibroblastic cell lines and other renal carcinoma cell lines. The growth-promoting activities were specifically blocked by monoclonal antibody 5F4.
منابع مشابه
Production and Characterization of a Monoclonal Antibody against an Antigen on the Surface of Non-Small Cell Carcinoma of the Lung
Background: Lung carcinoma is a multiple type cancer comprising of small cell and non-small cell carcinomas (NSCLC). For therapeutic and diagnostic purposes, serum monoclonal antibodies have been produced against lung cancer. Objective: To charac-terize a murine monoclonal antibody (ME3D11) reactive with human NSCLC. Methods: A murine monoclonal antibody (ME3D11) reactive with human NSCLC was s...
متن کاملCarcinoma Cells by Adriamycin Enhancement of Fas-mediated Apoptosis in Renal Cell
Anti-Fas monoclonal antibody (mAb) kills Fas-expressing cells by apoptosis. Several anticancer agents also mediate apoptosis and may share common intracellular pathways leading to apoptosis with Fas. Thus, we reasoned that combination treatment of drug-resistant cells with anti-Fas mAb and drugs might overcome their resistance. We investigated whether anticancer agents enhance Fas-mediated apop...
متن کاملImpact of Prolonged Fraction Delivery Time Modelling Stereotactic Body Radiation Therapy with High Dose Hypofractionation on the Killing of Cultured ACHN Renal Cell Carcinoma Cell Line
Introduction: Stereotactic body radiotherapy delivers hypofractionated irradiation with high dose per fraction through complex treatment techniques. The increased complexity leads to longer dose delivery times for each fraction. The purpose of this study is to investigate the impact of prolonged fraction delivery time with high-dose hypofractionation on the killing of cultured ACHN cells.Method...
متن کاملA Novel mAb against a Human CD34 Peptide Reacts with the Native Protein on CD34+ Cells
Background: Human CD34 is a transmembrane glycoprotein which is expressed in human hematopoietic stem cells (HSCs) and the small- vessel endothelial cells of a variety of tissues. CD34 plays a critical role as a marker for diagnosis and classification of leukemia. Anti CD34 antibodies are used for isolation and purification of HSCs from bone marrow, peripheral blood and cord blood. Objective: ...
متن کاملInhibition of telomerase activity in renal cell carcinoma cells by doxorubicin and anti-Fas monoclonal antibody.
Telomerase, the ribonucleoprotein enzyme that maintains the telomeres of eukaryotic chromosomes, is an attractive target for a mechanism-based therapeutic approach as its activation has been associated with unlimited proliferation in most types of cancer cells. Here, we investigated the effect of chemotherapeutic or immunotherapeutic agents and anti-Fas monoclonal antibody (mAb) on telomerase a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cancer research
دوره 50 10 شماره
صفحات -
تاریخ انتشار 1990